16 October 2017
To the Press and to whom it may concern
EFPIA Japan(European Federation of Pharmaceutical Industries and Associations)

EFPIA Japan Patient Organization Support Program “PASE”
First ever “PASE AWARD” winners decided
EFPIA Japan (European Federation of Pharmaceutical Industries and Associations) has made its firstever PASE AWARDs, selecting patient groups that particularly contribute to the evolution of Japan’s
patient advocacy and offering grants totaling 1.15 million yen. These grants have been made as part of“PASE (Patient Advocacy Support by EFPIA Japan (hereinafter, ’PASE’)”, which was established this July.
This year the “Grand Award” has been given to two groups, and the “Honor Award” has been given to
three groups, after a rigorous review of the proposals and activities of the total 29 groups that applied tothis program.

PASE AWARD winning organizations
AwardGrand Award

Award winning

Overview oforganization

application/proposal

CSR ProjectConduct a patient survey withGrant

500,000 JPY

the aim of providing information
to establish support for thebalance of work and cancer
treatments
Grand Award

Clavis Arcus

Launch an organization that

500,000 JPY

unifies parties affected bygenomic medicine and organize
disease awareness activities.
Honor Award

Advocacy Association ofOrganize patient support events 50,000 JPY

Allergic Patientswith the goal of raising healthliteracy and providing
self-management skills

Honor Award

One Step

Facilitate patient education

50,000 JPY

activities about how to establish
EFPIA Japan
Marunouchi Kitaguchi Building, 1-6-5 Marunouchi, Chiyoda-ku, Tokyo 100-8265
Tel: +81-3-6301-3066 Fax: +81-3-6301-3060

a sustainable universal
healthcare system
Honor Award

Japan IDDM network

Evaluate the social impact of50,000 JPY

the Bionic Artificial PancreasTransplantation Project
Ole Mølskov Bech, Chairman of EFPIA Japan, who sat on the selection committee of the first PASE
AWARDs, said: “I would like to express our appreciation to all the organizations that participated in ourvery first PASE AWARDs program. Selecting the winners of the Grand Award was extremely challenging
because the activities of all the patient organizations that applied were diverse in terms of disease areasand scale. I was very impressed and assured by how each group plays an important role in Japanese
healthcare society. I hope EFPIA Japan and all the patient groups that applied, including the two winnersof the Grand Award, can collaborate and together contribute to developing the Japanese healthcare
environment.”
The first PASE AWARDs invited active patient groups with legal entities to submit plans between 4 Julyand 31 August to utilize the PASE grant in Japan. The draft plans were reviewed and selected based on
five evaluation criteria: “contribution to healthcare throughout Japan”, “implementation of educational
activity on the disease itself and the related countermeasures”, “novelty of the proposed activity
compared with past activity performances”, “feasibility of the plan”, and “how important is the PASE grantin the proposed plan”. As a result, five out of the diverse 29 organizations were selected, and theirpresentations and Q&A sessions were reviewed. The PASE AWARDs final selection committee consistedof five individuals, including EFPIA Japan board members and an external senior advisor. The draft plans
were scored against the evaluation criteria, and the winners of the Grand Award were decided in a fairand objective manner.
The two organizations that won the Grand Award have each been offered a grant of 500,000 yen and areinvited to attend the presentation ceremony on 1 November this year. The three groups that won theHonor Award have been offered a grant of 50,000 yen and an opportunity to exchange further information
with EFPIA Japan. Details of the PASE AWARDs presentation ceremony will be notified separately.
Below is the list of organizations that applied for the first PASE grants. Please visit each website to learn
more about the activities of the individual organizations.

2017 PASE AWARD Applicant Organizations (in no particular order)
Organization

Disease AreaURLJapan Fabry Disease patients and familyFabry's disease

http://www.fabrynet.jp/

Gynecology

http://j-fine.jp/

association
Fine
Sagamihara Allergy no kai

http://www.sagamihara-allergy.org/

Allergy

Kirara (Breast cancer)

Breast cancer

http://www.nakagawak.jp/

PID Tsubasa

Primary

http://npo-pidtsubasa.org/

immunodeficiency
CSR ProjectCancer

XXXXXX

Intractable disease Patient organization desired not

http://workingsurvivors.org/

in children

to disclose their name

Cancer Support Community

Cancerhttp://www.csc-japan.org/

J-BREATH

Respiratory

http://www.j-breath.jp/

diseaseAllergy wo kangaeru hahanokai

Allergy

http://hahanokai.org/

JAPAN PARKINSON’S DISEASE

Parkinson’s

https://sites.google.com/site/jpdaorg/

ASSOCIATION

DiseaseAssociation of study for Pulmonary

PulmonaryHypertension

Hypertension

Clavis Arcus

Hereditary Breast

http://www.aphj.org/

http://www.clavisarcus.com/

and Ovarian
CancerJALSA, Japan Amyotrophic Lateral Sclerosis

ALS

http://alsjapan.org/

Japan IDDM network

Type 1 DM

http://japan-iddm.net/

Japan Multiple Sclerosis Society

Neurology

http://www.jmss-s.jp/

Nanbyou network

Intractable disease https://www.nanbyonet.or.jp/

Associationin children
Japan Association of Medical Translation forCancer

https://jamt-cancer.org/

Heart disease

http://www.heart-mamoru.jp/

CancerHeart -mamoru

Japan Federation of Cancer Patient Groups

CancerTourette Syndrome Association of Japan

Tourette Syndrome http://tourette-japan.org/

Advocacy Association of Allergic PatientsAllergyhttps://aalp201705.wixsite.com/aalp

Orange tea

Gynecological

http://o-tea.org/

http://zenganren.jp/

cancerRegistered Non Profit Organization Hospital

General

http://hps-japan.net/

NPO Kanja Speaker BankGeneral

http://npoksb.org/

NPO Prostate Cancer Patients Association

Prostate cancer

http://pc-pc.org/

Expert Patient in Respiratory Care

Respiratory

http://www.eparec.org/

Play Society JapandiseaseNPO Pancreatic Cancer Action Network

Pancreatic cancerhttp://www.pancan.jp/Lung cancer

http://www.lung-onestep.jp/

JapanOne Step

EFPIA Japan will continue to make efforts to realize “patient-centered healthcare” in Japan.
＃＃＃About the EFPIA Japan Patient Organization Support Program “PASE”“PASE (Patient Advocacy Support by EFPIA Japan)” is a patient organization support program newly
established with the goal of realizing the patient-centered thinking of EFPIA Japan. PASE is designed tohelp further vitalize patient group activities in Japan, and supports the healthcare environment
surrounding patients to evolve, so that it better reflects patients’ voices in the healthcare system.
As part of PASE, EFPIA Japan decided to conduct the PASE AWARDs, in which grants of 1.15 million yen
this year will be awarded to organizations that contribute to the evolution of patient advocacy (activities toprotect patient rights).
(http://efpia.jp/link/1706_Notifcation_EFPIA_PASE_JP.pdf).

First PASE final selection committee

Ole Mølskov Bech, Chairman, EFPIA Japan (Novo Nordisk Pharma Ltd)

Philippe Fauchet, Vice Chairman, EFPIA Japan (Glaxo SmithKline K.K.)

Jacques Nathan, Board of Director, EFPIA Japan (Sanofi K.K.)

Mariko Mimura, Committee Chair, Governance and Legal Committee, EFPIA Japan (GlaxoSmithKline K.K.)
Masuhiro Kato, Specially Appointed Professor, Translational Research Initiative, The University ofTokyo, and Senior Advisor of EFPIA Japan

About the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan
EFPIA Japan, established in April 2002, represents 24 R&D-based European pharmaceutical companies
operating in the Japanese market. Combined sales from the EFPIA member companies account for
approximately 25% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “contributeto healthcare and patients in Japan through the rapid introduction of innovative medicines and vaccines”.
EFPIA Japan aims to strengthen communication with policymakers for the improvement of Japanese
healthcare.

About the European Federation of Pharmaceutical Industries and Associations (EFPIA)EFPIA, headquartered in Brussels, the capital of Belgium, represents the pharmaceutical industry
operating in Europe. Through its direct membership of 33 national associations and 42 leading
pharmaceutical companies, EFPIA is the voice of 1,900 companies committed to developing and bringing
new treatments to patients around the world that will improve the quality of life.
Details can be found below.
http://efpia.jp/English/index-e.html (EFPIA Japan)
http://www.efpia.eu (EFPIA)

Inquiries to:
Noriko Okazaki, Committee Chair, Public Relations Committee, EFPIA Japan
Novo Nordisk Pharma Ltd.
2-1-1 Marunouchi, Chiyoda-ku, Tokyo 100-0005
TEL: 03-6266-1700
Mail: no@novonordisk.com
Yumiko Kurahashi, Public Relations Committee, EFPIA Japan
AstraZeneca K.K.
Marunouchi Trust Tower, 1-8-3 Marunouchi, Chiyoda-ku, Tokyo 100-0005
TEL : 03-6268-3857
Mail: Yumiko.Kurahashi@astrazeneca.com